Laboratory Animal Medicine Market Trends for 2026

The laboratory animal medicine market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2026 to 2035. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.

The laboratory animal medicine market is growing, as these medicines plays significant role in research for different disciplines such as toxicology, pharmacology, and physiology.

Key Takeaways

• North America dominated the Laboratory Animal Medicine Market in 2025.
• Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By product, the therapeutics & preventive medicines segment dominated the market in 2025.
• By product, the diagnostics & health surveillance products segment is expected to fastest growing in the market during the forecast period. 
• By animal model, the rodents segment dominated in 2025.
• By application, the disease surveillance & colony health monitoring segment dominated the market in 2025.
• By application, the chronic disease management & supportive care segment is expected to grow fastest in the market during the forecast period.
• By customer, the pharmaceutical & biopharmaceutical companies segment dominated the market in 2025.
• By customer, the preclinical CROs & contract laboratories segment is expected fastest growing in the market during the forecast period.

Market Overview: What is the Laboratory Animal Medicine Market?

The laboratory animal medicine market is increasing because this type of medicine is an increasing field of veterinary practice that emphasizes animal wellbeing and improvement of research animal health care. The applications of animals as experimental models remain a vital tool in the immediate future, enabling innovative and increasingly molecular discoveries of basic science to be translated into developments in health care for humans and animals alike. The laboratory animal medicines play an important role in the research community and society by managing and supporting the safeguarding of animals in research. Laboratory animal medicine is an exciting discipline that encompasses numerous fields that relate to the use of animals in teaching, research, and testing involving ethology, welfare, biology, genetics, biosafety, physiology, regulatory affairs, toxicology, and animal model advancement.

How is AI Governing the Laboratory Animal Medicine Market?

Integration of AI-driven technology in laboratory animal medicine drives market growth, as AI-driven technology has huge potential to play various roles in veterinary practice, enhancing the way veterinary care is delivered, enhancing results for animals, and eventually humans. The evolution of AI-based technology has led to a novel direction in biomedical research, particularly in translational research with massive potential, promising to transform science. AI is renovating science by lowering the requirement for animal testing and providing more ethical and humane substitutes. AI, in integration with organ-on-a-chip (OoC) and computer simulations, is allowing the advancement of animal digital twins, permitting scientists to predict biological technology.

Future Outlook & Trends in the Laboratory Animal Medicine Market

• Rise of In Vitro and Computational Alternatives: Bioinformatics has been evolving as a promising alternative to animal use and in vitro experiments, as it enables the investigation of biological phenomena using computational tools and biological databases.
• Increased Focus on Refinement: Refinement improves animal welfare by enhancing housing, handling, and investigational technology to reduce distress and pain. Refinements include non-invasive monitoring, efficient use of analgesia, and enrichment to help animals’ psychological and physical well-being.
• Genetically Modified Models: Genetically engineered models are more faithful than traditional models in terms of cancer advancement in humans and bypass a range of limitations of traditional models.

Segmentation Analysis

By Technology Insights

Which Therapeutics & Preventive Medicines Led the Laboratory Animal Medicine Market in 2025?

In 2025, the therapeutics & preventive medicines segment held the dominant market in 2025, due to its offer of priceless insights into human disease mechanisms, therapeutic and preventative targets, and treatment policies, making them crucial tools for translational research. The preventive medicine program is to reduce the probability of health challenges developing and to increase the chances of noticing health difficulties early. They offer significant insights into human disease mechanisms, preventative and therapeutic targets, and treatment approaches, making them vital tools for translational research.

Diagnostics & Health Surveillance Products

Whereas the diagnostics & health surveillance products segment is the fastest-growing in the market, as diagnostic products are significant tools to ensure the health of domestic and wild animals for both widespread and evolving diseases. Strategic investments in veterinary diagnostics allow earlier identification of animal diseases, prevent zoonotic outbreaks, reduce antibiotic misuse, progress food safety, and strengthen worldwide health security via coordinated, cross-sectoral exploit.

By Animal Model Insights

Why did the Rodents Segment Dominate the Market in 2025?

The rodents segment is dominant in the laboratory animal medicine market in 2025, and is expected maintain the fastest growth as rodents include their ease of maintenance, small size, limited life cycle, and massive genetic resources. Basic biomedical research includes the description of genes/proteins, the research of anatomical and physiological functions, and the characterization of normal and pathological situations in a diversity of animal species. Rodents are indispensable in biomedical research because of their physiological and genetic resemblances to humans, allowing in considerate diseases, advanced therapies, and safeguarding safety in drug testing.

By Application Insights

Why did the Disease Surveillance & Colony Health Monitoring Segment Dominate the Market in 2025?

The disease surveillance & colony health monitoring segment is dominant in the Laboratory animal medicine market in 2025, as these programs are critically important in rodent disease prevention; they offer data, the only reliable basis for rodent pathogen status or fitness quality assurance. The technology used in health surveillance usually involves serologic tests, bacterial cultures, histopathology, and parasitologic examinations. They are significant for confirming both high-quality research results and the welfare of the animals.

Chronic Disease Management & Supportive Care

Whereas the chronic disease management & supportive care segment is the fastest-growing in the market, integrating animals in the research helps researchers glean understandings faster. The laboratory animal medicine allows researchers to study processes like those involved in diseases of aging at a faster timescale. Novelties on the horizon in animal health provide the prospect of a world where the risk of disease is much reduced, stronger immunity, improved prevention approaches, earlier and precise diagnosis, and accurate and efficient treatment.

By Customer Insights

Why did the Pharmaceutical & Biopharmaceutical Companies Segment Dominate the Market in 2025?

The pharmaceutical & biopharmaceutical companies segment is dominant in the laboratory animal medicine market in 2025, as animal pharmaceutical companies play a significant role in safeguarding and improving the inclusive health of both livestock and pets via the development and distribution of pharma veterinary products. This invention range spans a diversity of interventions, like antibiotics, vaccines, antiparasitics, and nutritional supplements. Companies play a significant role in disease prevention policies. Vaccination programs are industrialized by animal pharmaceutical organizations.

Preclinical CROs & Contract Laboratories

Whereas the preclinical CROs & contract laboratories segment is the fastest-growing in the market, as outsourcing preclinical studies offers access to dedicated expertise, advanced technologies, and affordable services, leading to rapid project timelines and enhanced compliance with government standards. CROs are familiar with the government requirements, supporting organizations in navigating compliance requirements efficiently and reducing the challenges of government issues throughout submission processes.

Regional Insights

How did North America dominate the Market in 2025?

In 2025, North America dominated the laboratory animal medicine market due to its advanced pharmaceutical and academic research ecosystem. Spending in medical care innovation is increasing contributions to the American economy and solidifying the nation's role as a leader in healthcare innovation.  A strong presence of major pharmaceutical companies and specialized contract research organizations (CROs) such as Charles River Laboratories drives demand and invention in in-vivo models, which contributes to the growth of the market.

For Instance,

• In November 2025, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) had granted approval of KOMZIFTI for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 alteration who have no satisfactory substitute treatment selections.

U.S. Market Trends

In the U.S., the National Institutes of Health (NIH) is accepting a novel initiative to expand innovative, human-driven science while lowering animal use in research, making the U.S. the worldwide center for biomedical innovations. This region established strict ethical strategies and accreditation systems, such as AAALAC International, which was originally established as the American Association for the Accreditation of Laboratory Animal Care, which endorses the humane treatment of animals in science via voluntary assessment and accreditation.

Asia Pacific: Increasing Healthcare Capabilities

Asia Pacific is expected to see rapid growth in the laboratory animal medicine market, driven by a worldwide hub for biomedical and pharmaceutical research, with China, Japan, and India leading in the advancement of sophisticated, standardized animal services. Due to advancements in biodiversity, experiencing rapid land-use modification, the region has seen extensive habitat loss, increasing human-wildlife integration, and high levels of unregulated wildlife trade, which drives the growth of the market.

India Market Trends

India has more than 2300 animal services registered with CPCSEA for leading experiments using animals.  India is transitioning from traditional animal-based to advanced human-relevant technology, such as AI and organoids. This transformation aims to enhance drug achievement rates and establish India as a worldwide revolution hub. India's bio-pharmaceutical industry, ranked third worldwide in terms of volume, is the major supplier of generic drugs worldwide and an advocate of advanced-quality.

Europe: Advancement in Technology

Europe is growing significantly in the laboratory animal medicine market, as EU legislation is unique, as it sets a concluding aim of full replacement of animal applications for scientific and educational purposes, and is taking concrete action towards that goal. EU strategies have led to efforts to enhanced enforcement of legislation and to the spending of significant research on animal welfare by the European Commission. Encouraging high standards of laboratory animal medicine via scientific inquiry, which contributes to the growth of the market.

Value Chain Analysis

R&D

• Research and Development (R&D) in laboratory animal medicine includes a systematic technology of scientific investigation to advance animal health, enhance diagnostic abilities, and develop novel treatments.
• Key Players: American College of Laboratory Animal Medicine (ACLAM) and AALAS

Manufacturing Processes

• Manufacturing processes in laboratory animal medicine include an integration of extremely regulated pharmaceutical production for animal health products and specialized technology for the care, maintenance, and experimental operation of research animals.
• Key Players: ICLAS (International Council for Laboratory Animal Science)

Patient Services

• Patient services in laboratory animal medicine refer to the inclusive veterinary medical care, health surveillance, and support provided to animals used in biomedical studies, testing, and awareness.
• Key Players: ILAR (Institute for Laboratory Animal Research)

Latest Updates of Key Players in the Laboratory Animal Medicine Market

SWOT Analysis

Strengths

• Laboratory animal medicine provides priceless insights into human disease mechanisms, preventative and therapeutic targets, and management strategies, making them significant tools for translational research.
• Researchers use animals to study more related health challenges that affect both humans and animals, and to ensure the safety of novel healthcare management.

Weaknesses

• Investigational animals are virtually tortured to death, and these tests are done in the interest of human welfare, deprived of any knowledge of how the animals are treated.

Opportunities

• Modern animal models for biomedical research continue to be far improved than substitutes. They are used alongside novel computational technologies and human-driven models.
• Use of pre-emptive analgesics significantly lowers the required concentration of anesthetic gases, ensuing in minimization of respiratory and cardiovascular depression secondary to volatile anesthetics and a rapid recovery from anaesthesia.

Threats

• Animal models often do not precisely replicate human biology, resulting in unreliable information.
• Animal studies are costly, need specialized staff and amenities, and often prolong the drug development process.

Recent Developments in the Laboratory Animal Medicine Market

• In November 2025, Zoetis Inc. announced the acquisition of Veterinary Pathology Group (VPG), a foremost veterinary diagnostic laboratory group with multiple locations in Ireland and the UK. The acquisition also expands Zoetis’ comprehensive diagnostics selection and reinforces its commitment to progressing animal health via innovative and high-quality diagnostic solutions.
• In June 2025, Novartis announced that it completed its acquisition of Regulus Therapeutics Inc. By the completion of the acquisition, shares of common stock, par value $0.001 per share, of Regulus ceased trading on the Nasdaq Stock Market LLC, and Regulus is nowadays an indirect, exclusively owned subsidiary of Novartis

Segments Covered in the Report

By Product

• Diagnostics & Health Surveillance Products
  • Serology & PCR Test Kits
  • Microbiology & Parasitology Assays
  • Clinical Chemistry & Hematology Reagents / Panels
  • Others
• Therapeutics & Preventive Medicines
  • Vaccines
  • Anti-infectives (Antibiotics, Antivirals, Antifungals)
  • Antiparasitics (Endo- & Ecto-parasite Control)
  • Analgesics & Sedatives
  • Anesthetics
  • Anti-inflammatory & Supportive Care Drugs
  • Others
• Clinical Care Devices & Equipment
  • Animal Patient Monitoring Devices
  • Anesthesia Machines & Vaporizers
  • Ventilators & Respiratory Support Systems
  • Infusion & Syringe Pumps
  • Clinical Imaging & Diagnostic Devices
  • Others
• Clinical & Welfare Consumables
  • Needles, Syringes, Catheters & Vascular Access Sets
  • Bandages, Wound Care & Surgical Consumables
  • Disinfectants, Detergents & Sanitation Products
  • Personal Protective Equipment (PPE) & Barrier Consumables
  • Others
• Other Products

By Animal Model

• Rodents
• Rabbits
• Non-Human Primates (NHPs)
• Others

By Application

• Disease Surveillance & Colony Health Monitoring
• Preventive Care & Biosecurity
• Perioperative Care (Anesthesia, Analgesia, Surgical Support)
• Chronic Disease Management & Supportive Care
• Welfare & Behavioral Assessment
• End-of-Life & Euthanasia Management
• Training, Education & Compliance Support
• Others

By Customer

• Pharmaceutical & Biopharmaceutical Companies
• Preclinical CROs & Contract Laboratories
• Academic & Research Institutions
• Others

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA